Emma Walmsley
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
UK's GSK to acquire U.S. drugmaker Nuvalent for $10.6 billion as pharma giants race to expand pipelines
U.K. pharmaceutical group GSK has entered an agreement to acquire U.S.-based drugmaker Nuvalent for $10.6 billion to bolster its lung cancer pipeline, in what would be the British drugmaker's largest acquisition in more than a decade. The all-cash deal values Nuvalent at about $124 per share, according to a GSK filing on Tuesday, representing a 40% premium to its last closing price. The Financial Times had reported the transaction earlier on Tuesday.